Project Grant R01HL172803
Award Date
1/15/25
Completion Date
12/31/27
Dollars Obligated
$1.4M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $104,933 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University. The grant supports research to determine the role of age-related clonal hematopoiesis of indeterminate potential (CHIP), an inflammatory biomarker, in cardiorespiratory fitness (CRF) and cardiometabolic responses to chronic exercise interventions. The project aims to evaluate whether CHIP is associated with baseline CRF and...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $165,080 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Dana-Farber Cancer Institute (DFCI) in Boston, MA. The grant will fund a 5-year research project led by Dr. Lachelle D. Weeks to define the relationship between clonal hematopoiesis (CH) and inflammatory disease outcomes. The project aims to: 1) Determine the association between CH and rheumatologic diseases, 2) Identify CH genotypes...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The award, effective July 15, 2024 through June 30, 2028, will support research to: (1) identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
This Project Grant award of $602,358, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to assess the contribution of epigenetics to cardiovascular risk in African American women. The project will identify epigenetic biomarkers of cardiovascular disease and its environmental determinants, and evaluate if these biomarkers can contribute to risk prediction assessments. The research will be conducted by the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This $680,321 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to elucidate how the protein DLK1 regulates hematopoietic stem cell (HSC) quiescence through inhibition of receptor signaling pathways. The research aims to determine if DLK1 maintains and/or expands quiescent HSCs, how DLK1 interactions with receptor components within condensates alters receptor signaling, and whether...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $285,608 Project Grant to the University of North Carolina at Chapel Hill. The grant aims to (1) investigate whether cough symptoms can predict responses to treatments for Cough Hypersensitivity Syndrome (CHS), and (2) determine the feasibility of a pilot randomized controlled trial of a non-pharmacologic treatment, Acceptance and Commitment Therapy, for CHS...
This $132,410 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide protected time for Dr. Cheryl Anderson, a mid-career clinical investigator, to recruit and mentor a diverse group of trainees in clinical cardiovascular epidemiology and health equity research. The award will support two new areas of research: 1) integrating global policy and strategy into multilevel interventions to improve...